CXCL10 and non-Hodgkin lymphoma: Vendrame and colleagues found that sustained elevation of CXCL10 in the three-time windows prior to HIV-NHL diagnosis (>3 years, 1–3 years, and 0–1 year) increased the risk of morbidity by more than 3.7-10-fold, and high CXCL10 levels correlated with adverse prognosis significantly [55].